Wang, D.; Chang, A.; Shea, F.; He, Y.; Spinney, R.; Whitsett, J.D.; Lahann, J.; Mallery, S.R.
Engineered Fenretinide- and Tocilizumab-Releasing Janus Nanoparticles for Site-Directed Immunochemoprevention of Squamous Cell Carcinoma of the Lung. Pharmaceutics 2025, 17, 1471.
https://doi.org/10.3390/pharmaceutics17111471
AMA Style
Wang D, Chang A, Shea F, He Y, Spinney R, Whitsett JD, Lahann J, Mallery SR.
Engineered Fenretinide- and Tocilizumab-Releasing Janus Nanoparticles for Site-Directed Immunochemoprevention of Squamous Cell Carcinoma of the Lung. Pharmaceutics. 2025; 17(11):1471.
https://doi.org/10.3390/pharmaceutics17111471
Chicago/Turabian Style
Wang, Daren, Albert Chang, Fortune Shea, Yifei He, Richard Spinney, Jonathan D. Whitsett, Joerg Lahann, and Susan R. Mallery.
2025. "Engineered Fenretinide- and Tocilizumab-Releasing Janus Nanoparticles for Site-Directed Immunochemoprevention of Squamous Cell Carcinoma of the Lung" Pharmaceutics 17, no. 11: 1471.
https://doi.org/10.3390/pharmaceutics17111471
APA Style
Wang, D., Chang, A., Shea, F., He, Y., Spinney, R., Whitsett, J. D., Lahann, J., & Mallery, S. R.
(2025). Engineered Fenretinide- and Tocilizumab-Releasing Janus Nanoparticles for Site-Directed Immunochemoprevention of Squamous Cell Carcinoma of the Lung. Pharmaceutics, 17(11), 1471.
https://doi.org/10.3390/pharmaceutics17111471
